AU2001239517A1 - Single chain antibody against mutant p53 - Google Patents

Single chain antibody against mutant p53

Info

Publication number
AU2001239517A1
AU2001239517A1 AU2001239517A AU3951701A AU2001239517A1 AU 2001239517 A1 AU2001239517 A1 AU 2001239517A1 AU 2001239517 A AU2001239517 A AU 2001239517A AU 3951701 A AU3951701 A AU 3951701A AU 2001239517 A1 AU2001239517 A1 AU 2001239517A1
Authority
AU
Australia
Prior art keywords
single chain
chain antibody
antibody against
mutant
against mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001239517A
Inventor
Gerald Cohen
Dimitri Govorko
Beka Solomon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of AU2001239517A1 publication Critical patent/AU2001239517A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

More than 90% of mutations found in the p53 protein produce a conformational change in p53 which results in the exposure of an epitope, which is otherwise hidden in the hydrophobic core of the molecule. A single chain antibody (scFv) which specifically recognizes this common mutant epitope in mutant p53 but not in wild type p53 is disclosed. Also described are a DNA molecule encoding the scFv, pharmaceutical compositions comprising the antibody and methods of treatment using the pharmaceutical compositions.
AU2001239517A 2000-03-16 2001-03-09 Single chain antibody against mutant p53 Abandoned AU2001239517A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09526738 2000-03-16
US09/526,738 US6630584B1 (en) 2000-03-16 2000-03-16 Single chain antibody against mutant p53
PCT/IL2001/000225 WO2001068801A2 (en) 2000-03-16 2001-03-09 Single chain antibody against mutant p53

Publications (1)

Publication Number Publication Date
AU2001239517A1 true AU2001239517A1 (en) 2001-09-24

Family

ID=24098588

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001239517A Abandoned AU2001239517A1 (en) 2000-03-16 2001-03-09 Single chain antibody against mutant p53

Country Status (6)

Country Link
US (2) US6630584B1 (en)
EP (1) EP1272609B1 (en)
AT (1) ATE353335T1 (en)
AU (1) AU2001239517A1 (en)
DE (1) DE60126482T2 (en)
WO (1) WO2001068801A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630584B1 (en) * 2000-03-16 2003-10-07 Ramot At Tel-Aviv University Ltd. Single chain antibody against mutant p53
US20060263837A1 (en) * 2004-06-17 2006-11-23 Liu George D Immunoassay system and method for detection of antigens
US7799556B2 (en) * 2004-06-17 2010-09-21 George Dacai Liu System and method for antigen structure-independent detection of antigens captured on antibody arrays
DK1781315T3 (en) * 2004-08-23 2015-04-20 Yeda Res & Dev PEPTIDE INHIBITORS FOR MEDIATION OF stress responses
WO2006100681A2 (en) * 2005-03-25 2006-09-28 Ramot At Tel Aviv University Ltd. Human synthetic single-chain antibodies directed against the common epitope of mutant p53 and their uses
AU2006311661B2 (en) 2005-11-07 2011-05-26 The Scripps Research Institute Compositions and methods for controlling tissue factor signaling specificity
WO2010002862A2 (en) * 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
GB2482536B (en) 2010-08-05 2013-07-24 Hera Pharmaceuticals Inc Expression of antibody or a fragment thereof in lactobacillus
US20140088017A1 (en) 2011-05-23 2014-03-27 Yeda Research And Development Co., Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
WO2014093417A1 (en) 2012-12-12 2014-06-19 University Of Virginia Patent Foundation Compositions and methods for regulating erythropoiesis
EP2958584A1 (en) * 2013-02-20 2015-12-30 Yeda Research and Development Co., Ltd. Interferon treatment targeting mutant p53 expressing cells
WO2016081897A1 (en) 2014-11-21 2016-05-26 University of the Sciences of Philadelphia COMPOSITIONS AND METHODS OF USING THERAPEUTIC p53 PEPTIDES AND ANALOGUES
CN108137685B (en) * 2015-03-23 2022-11-11 约翰·霍普金斯大学 HLA-restricted epitopes encoded by somatic mutation genes
GB201617564D0 (en) 2016-10-17 2016-11-30 Agency For Science Technology And Research And National University Of Singapore And Singapore Health Anti-p53 antibodies
WO2018213467A1 (en) 2017-05-16 2018-11-22 The Johns Hopkins University Manabodies and methods of using
CN113528467B (en) * 2021-06-24 2023-12-01 新乡学院 Targeting double-display phage and preparation method and application thereof
CA3234720A1 (en) * 2021-10-08 2023-04-13 Sola Biosciences Llc Compositions and methods for the treatment of p53-mediated cancers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPH09505735A (en) * 1993-11-22 1997-06-10 オニックス ファーマシューティカルズ，インコーポレイティド p53-binding polypeptides and polynucleotides encoding same
FR2755144B1 (en) * 1996-10-29 1998-11-27 Rhone Poulenc Rorer Sa SINGLE CHAIN ANTI-P53 ANTIBODY FRAGMENTS AND USE THEREOF
US20020155114A1 (en) * 1998-08-31 2002-10-24 James D. Marks Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US6630584B1 (en) 2000-03-16 2003-10-07 Ramot At Tel-Aviv University Ltd. Single chain antibody against mutant p53

Also Published As

Publication number Publication date
WO2001068801A2 (en) 2001-09-20
DE60126482T2 (en) 2007-11-29
DE60126482D1 (en) 2007-03-22
WO2001068801A3 (en) 2002-02-07
ATE353335T1 (en) 2007-02-15
EP1272609A4 (en) 2004-12-22
EP1272609A2 (en) 2003-01-08
US7288637B2 (en) 2007-10-30
EP1272609B1 (en) 2007-02-07
US20030022244A1 (en) 2003-01-30
US6630584B1 (en) 2003-10-07

Similar Documents

Publication Publication Date Title
AU2001239517A1 (en) Single chain antibody against mutant p53
EP2289550A3 (en) Ultra high affinity neutralizing antibodies
WO2004032868A3 (en) Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
AU2002341920A1 (en) Chemical compounds
WO2005061545A3 (en) Nogoa antibodies for the treatment of alzheimer disease
WO2003014325A3 (en) Protein design automation for protein libraries
AU2002235994A1 (en) Method for producing proteins by fermentation of microorganisms from the thermus family, the protein mixture thus obtained and cosmetic compositions containing same
WO2001059066A3 (en) Protein design automation for protein libraries
WO2000023564A3 (en) Protein design automation for protein libraries
MXPA02011656A (en) Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods.
MY153718A (en) Formulation of human antibodies for treating tnf-(?) associated disorders
AU2002366644A1 (en) Method for administering birb 796 bs
NO974572D0 (en) Cyclodextrin Compounds, Methods of Preparation and Use
AU2002253126A1 (en) Use of creatine, creatinine and/or derivatives thereof
AU2002239491A1 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
WO2003075855A3 (en) Antibodies against cancer antigen tmeff2 and uses thereof
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
DE60129278D1 (en) Antibodies directed against the SEMP1 protein, process for their preparation, and their uses
MXPA02012249A (en) Peptides, compositions and methods for the treatment of burkholderia cepacia.
AU2002359495A1 (en) Anti-tnf antibodies, compositions, methods and uses
AU4876196A (en) A process for the preparation of factor ix from biological sources
WO2002102318A3 (en) Eglin c based drugs for treatment of disease
AU2001250999A1 (en) Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
AU2002239256A1 (en) Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
WO2003059387A3 (en) Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis